CNXU Conexeu Sciences Inc. - Common Stock
$10.86
Price · Jul 2, 2026
Fundamentals as of Jun 15, 2026
52W Range
$10–$19
14% of range
Analyst Rating
—
Price Target
$20
+84% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
CNXU Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.86
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$10 – $19
CNXU Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
CNXU
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
CNXU
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
CNXU
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
CNXU
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
CNXU
Peer Median
CNXU Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-07-03
Low
$20.00
High
$20.00
Median target
$20.00
+84.2%
Mean target
$20.00
+84.2%
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CNXU | — | — | — | — | — | — |
| FHTX | $306M | -4.6 | 36.8% | -240.3% | 80.2% | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | — |
| GALT | $271M | -8.7 | — | — | 25.0% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| TLSI | — | — | — | — | — | — |
| IKT | $270M | -4.2 | 111.0% | -1299.0% | -38.2% | — |
| IVVD | $697M | -8.2 | 110.5% | -98.2% | -36.9% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 15
| Metric | Trend | Q2 2026 |
|---|---|---|
| R&D Expense | $66.6K | |
| SG&A Expense | $16.9K | |
| Operating Expenses | $2M | |
| Operating Income | $-2M | |
| Interest Expense | $0 | |
| Interest Income | $84.3K | |
| Other Non-op | $76.1K | |
| Pretax Income | $-2M | |
| Income Tax | $0 | |
| Net Income | $-2M | |
| EPS (Basic) | $-0.11 | |
| EPS (Diluted) | $-0.11 | |
| Shares (Basic) | 20,569,664 | |
| Shares (Diluted) | 20,569,664 | |
| EBITDA | $-2M |
Balance Sheet 16
| Metric | Trend | Q2 2026 |
|---|---|---|
| Cash & Equivalents | $7M | |
| Prepaid Expense | $609.5K | |
| Current Assets | $8M | |
| PP&E (Net) | $38.4K | |
| PP&E (Gross) | $49.1K | |
| Accum. Depreciation | $10.7K | |
| Intangibles | $163.9K | |
| Total Assets | $8M | |
| Accounts Payable | $455.1K | |
| Total Liabilities | $1M | |
| Common Stock | $20.9K | |
| Paid-in Capital | $16M | |
| Retained Earnings | $-9M | |
| Stockholders' Equity | $7M | |
| Liabilities + Equity | $8M | |
| Shares Outstanding | 20,916,173 |
Cash Flow 1
| Metric | Trend | Q2 2026 |
|---|---|---|
| D&A | $11.4K |
Profitability 3
| Metric | Trend | Q2 2026 |
|---|---|---|
| ROA | -56.2% | |
| ROE | -64.0% | |
| ROIC | -33.1% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.